Move Over Pharma: Patient-Led Organizations Advance Rare Disease Clinical Trials
At the 2025 SCOPE Summit, industry leaders and patient advocates discussed a transformative shift in the pharmaceutical industry: patient-led...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials Alzheimer's Disease Article Artificial Intelligence in Clinical Trials Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage CRO Consolidation Decentralized Clinical Trials Digital Health Technologies dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
At the 2025 SCOPE Summit, industry leaders and patient advocates discussed a transformative shift in the pharmaceutical industry: patient-led...
Opus Genetics announced positive Phase 3 results for its Phentolamine Ophthalmic Solution 0.75% in patients with dim light disturbances,...
Clearmind Medicine Inc. (Nasdaq: CMND) has shipped its novel psychedelic-derived drug candidate, CMND-100, to the United States for its...
Silexion Therapeutics has developed an expanded plan for SIL204, its next-generation siRNA candidate targeting KRAS-driven cancers. The company will...
Opthea Limited’s Phase 3 COAST trial for sozinibercept, a combination therapy with aflibercept for wet age-related macular degeneration (wet...
In the dynamic world of pharmaceuticals, staying ahead of trends and challenges is vital. Graham Clark, CEO of Phastar,...
Nanobiotix announced two poster presentations at the 2025 European Lung Cancer Conference showcasing Phase 1 study data for JNJ-1900...
Dyadic International received a $4.5 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to explore using their...
BriaCell Therapeutics Corp. announced positive safety results from the second review of its Phase 3 study of Bria-IMT™ combined...
Medera Inc., a clinical-stage biopharmaceutical company, announced positive results from the Phase 1b portion of its MUSIC-HFrEF trial, evaluating...